| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
PBIT targets nitric oxide synthase (NOS) isoenzymes, including inducible NOS (iNOS), neuronal NOS (nNOS), and endothelial NOS (eNOS). It has Ki values of 7.6 nM, 16 nM, and 360 nM for iNOS, nNOS, and eNOS, respectively. By inhibiting NOS, PBIT reduces nitric oxide production, which is involved in inflammation, neurotransmission, and vasodilation. PBIT also prevents proliferation of JARID1B-expressing cells.
|
|---|---|
| ln Vitro |
PBIT prevents cells that express more JARID1B from proliferating. In a JARID1B level-dependent manner, PBIT (1-10 μM for UACC-812 cells and 2.5-10 μM for MCF7 and MCF10A cells; 72 hours) reduces cell proliferation [1].
In vitro, PBIT potently inhibits NOS isoenzymes with Ki values of 7.6 nM (iNOS), 16 nM (nNOS), and 360 nM (eNOS). PBIT (1-10 μM) reduces cell proliferation in a JARID1B level-dependent manner in UACC-812 cells and MCF7 and MCF10A cells. The compound significantly depresses LPS-induced mRNA expressions of iNOS and IL-1β. |
| ln Vivo |
In vivo activity data for PBIT (CAS 157254-60-9) are not extensively detailed in the available literature. As a potent NOS inhibitor, the compound would be expected to reduce nitric oxide production and modulate inflammatory responses in vivo. Its effects on iNOS and IL-1β expression suggest potential anti-inflammatory activity.
|
| Enzyme Assay |
Specific cell-free enzyme/receptor binding assay protocols for PBIT involve NOS enzyme activity assays using purified recombinant NOS isoforms (iNOS, nNOS, eNOS). Enzyme activity is measured by monitoring the conversion of L-arginine to L-citrulline using radiolabeled arginine or by detecting nitric oxide production using chemiluminescence. Ki values are determined from competitive inhibition curves.
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: Human breast cancer cell lines (UACC-812 and MCF7) and human mammary epithelial cells (MCF10A) Tested Concentrations: 1, 3, and 10 μM for UACC-812 cells; 2.5, 5, and 10 μM for MCF7 and MCF10A cells Incubation Duration: 72 hrs (hours) Experimental Results: Inhibited cell proliferation in a JARID1B level-dependent manner. 10 μM killed most of the UACC-812 cells, but demonstrated minimal toxicity to MCF7 cells and MCF10A cells. In vitro cell-based assays for PBIT use cell lines such as UACC-812, MCF7, and MCF10A cells. Cells are treated with PBIT (1-10 μM for 72 hours), and cell proliferation is measured using MTT or BrdU assays. JARID1B expression levels are assessed by Western blot. LPS-induced iNOS and IL-1β mRNA expression is measured by qPCR. |
| Animal Protocol |
In vivo animal studies for PBIT are not detailed in the available literature. As an NOS inhibitor with anti-inflammatory potential, typical in vivo evaluation would involve models of inflammation (such as LPS-induced endotoxemia) to assess the compound's effects on nitric oxide production and inflammatory cytokine expression.
|
| ADME/Pharmacokinetics |
PBIT (1,4-PBIT dihydrobromide) has a molecular formula of C12H20Br2N4S2 and a molecular weight of 444.25 g/mol. The compound is supplied as a solid powder and is soluble in DMSO. Purity is typically ≥98%. Storage: dry, dark, at 0-4°C for short term or -20°C for long term.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for PBIT are not detailed in the available literature. The compound is classified for research use only and is not intended for human therapeutic applications. As a NOS inhibitor that reduces nitric oxide production, potential toxicities may relate to effects on blood pressure regulation and immune function.
|
| References | |
| Additional Infomation |
PBIT (CAS 157254-60-9), also known as 1,4-PBIT dihydrobromide, is a potent NOS inhibitor with Ki values of 7.6 nM (iNOS), 16 nM (nNOS), and 360 nM (eNOS). It also prevents proliferation of JARID1B-expressing cells and depresses LPS-induced iNOS and IL-1β mRNA expression. No clinical trial or approved indication data are available.
|
| Molecular Formula |
C12H18N4S2.2[HBR]
|
|---|---|
| Molecular Weight |
444.252
|
| Exact Mass |
441.949
|
| CAS # |
157254-60-9
|
| PubChem CID |
11957667
|
| Appearance |
Off-white to brown solid powder
|
| LogP |
5.541
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
20
|
| Complexity |
247
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
YRRYHMLYGVNPBW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H18N4S2.2BrH/c13-11(14)17-7-5-9-1-2-10(4-3-9)6-8-18-12(15)16;;/h1-4H,5-8H2,(H3,13,14)(H3,15,16);2*1H
|
| Chemical Name |
2-[4-(2-carbamimidoylsulfanylethyl)phenyl]ethyl carbamimidothioate;dihydrobromide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2510 mL | 11.2549 mL | 22.5098 mL | |
| 5 mM | 0.4502 mL | 2.2510 mL | 4.5020 mL | |
| 10 mM | 0.2251 mL | 1.1255 mL | 2.2510 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
